Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?
OBJECTIVE
Both the metabolic syndrome and prediabetes are associated with increased coronary risk. Lipoprotein abnormalities are among the many factors that may contribute to this. The present review focuses on these abnormalities and the evidence indicating that correcting them may reduce the risk.


RESULTS
Many drugs, both old and in development, may be able to correct lipoprotein abnormalities. No clinical trials are specifically designed to examine the effects of lipid intervention on coronary risk in the metabolic syndrome. Data from subgroup analyses and extrapolation from studies in those with and without diabetes have led to recommendations about the benefits and the targets for lipoprotein treatment.


CONCLUSIONS
The primary goal of lipoprotein treatment is to bring the LDL-C to target levels. Thereafter, if plasma triglycerides are high and HDL-C is low, these should be corrected.
Steiner
George
G
Department of Medicine, Division of Endocrinology and Metabolism, University of Toronto and Toronto General Hospital, Toronto, Ontario, Canada. george.steiner@uhn.on.ca
D002318:Cardiovascular Diseases / Q000453:epidemiology; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008074:Lipoproteins / Q000097:blood; D004364:Pharmaceutical Preparations; D011236:Prediabetic State / Q000097:blood* / Q000188:drug therapy* / Q000453:epidemiology; D012307:Risk Factors
D008074:Lipoproteins; D004364:Pharmaceutical Preparations